Table 4:
Use of antihypertensive, lipid-lowering and smoking-cessation medications among participants in the heart-health intervention (n = 211) and control (n = 215) groups at baseline and follow-up
| Medication, no. (%) | Baseline | 3 mo | 12 mo | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| Heart-health intervention | Control | p* | Heart-health intervention | Control | p* | Heart-health intervention | Control | p* | |
| Antihypertensive | 67 (31.7) | 52 (24.2) | 0.08 | 74 (35.1) | 58 (26.9) | 0.07 | 79 (37.4) | 66 (30.6) | 0.1 |
|
| |||||||||
| Lipid-lowering | 42 (19.9) | 51 (23.7) | 0.3 | 45 (21.3) | 54 (25.1) | 0.4 | 47 (22.3) | 61 (28.3) | 0.2 |
|
| |||||||||
| Smoking cessation† | 1 (5.0) | 2 (10.5) | 0.6 | 7 (35.0) | 2 (10.5) | 0.07 | 5 (25.0) | 3 (15.7) | 0.5 |
*
χ2 test.
†
Based on 20 smokers in the heart-health intervention group and 19 smokers in the control group.